- Home
- RIGL vs OWLS Comparison
RIGL vs OWLS Comparison
Compare RIGL & OWLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | OWLS |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 564.7M | 508.2M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | RIGL | OWLS |
|---|---|---|
| Price | $29.36 | $5.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $45.67 | $11.00 |
| AVG Volume (30 Days) | ★ 313.7K | 33.6K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 19.48 | N/A |
| Revenue | ★ $294,282,000.00 | N/A |
| Revenue This Year | N/A | $6.57 |
| Revenue Next Year | $12.75 | $375.69 |
| P/E Ratio | $1.48 | ★ N/A |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $16.88 | $5.15 |
| 52 Week High | $52.24 | $29.00 |
Technical Indicators
Market Signals| Indicator | RIGL | OWLS |
|---|---|---|
| Relative Strength Index (RSI) | 46.01 | 52.80 |
| Support Level | $28.08 | $5.83 |
| Resistance Level | $30.59 | $6.21 |
| Average True Range (ATR) | 1.13 | 0.33 |
| MACD | -0.22 | 0.02 |
| Stochastic Oscillator | 16.16 | 65.33 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About OWLS OBOOK Holdings Inc.
OBOOK Holdings Inc is focused on using blockchain technology to provide inventive solutions to customers in various sectors, including financial services, hospitality, and e-commerce. Through its e-commerce, hospitality and payments offerings, it is committed to serving businesses and individuals whose commercial activities involve cross-border transactions.